Groupe d'Etude en Oncologie du Quebec

Titre	A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Protocole ID	MAHOGANY
ClinicalTrials.gov ID	NCT05100862
Type(s) de cancer	Lymphome non-hodgkinien (LNH)
Phase	Phase III
Stade	Récidivant/réfractaire (2ième ligne de traitement et plus)
Type étude	Clinique
Médicament	Zanubrutinib + anticorps Anti-CD20 versus lénalidomide + rituximab
Institution	CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE HOPITAL FLEURIMONT 3001 12e Avenue Nord, Sherbrooke, QC, J1H 5N4
Ville	Sherbrooke
Investigateur(trice) principal(e)	Dre Dominique Toupin
Coordonnateur(trice)	Michelle Roy 819-346-1110 poste 12848
Statut	Actif en recrutement
Date d'activation	06-08-2024
Critètes d'éligibilité	Key Inclusion Criteria: Histologically confirmed grade 1-3a FL or MZL Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy Need for systemic therapy for FL or MZL Measurable disease by computed tomography or magnetic resonance imaging Adequate bone marrow, liver and renal function
Critètes d'exclusion	Key Exclusion Criteria: Transformation to aggressive lymphoma Requiring ongoing need for corticosteroid treatment Clinically significant cardiovascular disease Prior malignancy within the past 2 years Active fungal, bacterial, and/or viral infection that requires systemic therapy Prior treatment with lenalidomide or drug from same class, if without response (partial or complete) or short remission duration (< 24 months)

Groupe d'étude en oncologie du Québec